The Pharmaceuticals Division focuses on prescription drugs for the therapeutic areas of cardiology, oncology, gynecology, hematology and ophthalmology. With its innovative pharmaceutical products, Bayer seeks to achieve a significant therapeutic benefit for patients while at the same time satisfying the growing requirements of physicians and health insurers. The Pharmaceuticals division in China is headquartered in Beijing with facilities in Beijing and Guangzhou.
Bayer constructed a pharmaceutical production and packaging facility in Beijing from 1995 to 1997, manufacturing solid and semisolid products. To meet the growing needs of the Chinese market, the company invested significantly in the extension of the company’s Beijing site. The site increased its production capacity several times following the extension and was equipped with state-of-the-art technology. In 2011, the Beijing site received the “Good Manufacturing Practice” certification from the Beijing Drug Administration Bureau.
In anticipation of increasing product demand in China, Bayer invested EUR 100 million to significantly increase the production capacity of its Beijing plant. The capacity extension is designed to ensure a reliable supply of high-quality products to meet the Chinese market’s demand for pharmaceutical products, including the company’s cardiovascular and anti-diabetes products. The extension includes improved logistics for fully automated material handling, analytical laboratories, and high-speed packaging lines.
At the same time, Bayer is forming long-term strategic alliances with well-known academic institutes worldwide to drive fundamental research and explore the frontiers of drug discovery. In China, Bayer is strengthening the partnerships and strategic alliances with leading Chinese academic institutes such as Tsinghua University, Peking University and the Shanghai Institute of Organic Chemistry, to accelerate the translation of fundamental research into clinical treatment and improve China’s pharmaceutical innovation and R&D capabilities. In March 2018, Bayer celebrated its ten years of partnership with Tsinghua University and the two sides extended their strategic partnership to extend the innovative drug discovery alliance for another three years.
Bayer was one of the earliest companies to focus on county-level medical service capabilities in China and continues to invest in this area. Over the past ten years, over 45,000 physicians and hospital executives across 26 provinces have been trained under the “Go West” project. In 2018, the “Go West” project officially entered the third five-year period. In the next five years, the project will be extended to 31 provinces, cities, and regions around the country to increase the coverage outside the central and western regions.
The Pharmaceuticals Division’s Radiology business is a world-renowneddiagnostic imaging solutions provider. In the field of Radiology, Bayer provides solution with imaging contrast media, injection devices and informatics in China. Bayer is seen as the leading expert bringing Chinese radiologists and society to the best science through robust education programs. Supported by the legacy Ultravist in CT modality and Madred injectors, Bayer is also seen as the innovation leader in MR portfolio by Gadovist with whole body indication and liver specific Primovist.
Consumer Health Division
Bayer’s Consumer Health Division is a leader in the global consumer health marketplace. It operates in more than 100 countries and maintains several manufacturing and research-and-development (R&D) sites.
The division’s rich history of innovation began in 1899 with the introduction of Bayer’s flagship global consumer brand, Bayer Aspirin®. In 2005, Bayer acquired Roche’s OTC business and in October 2014 Bayer completed the acquisition of Merck’s global Consumer Care business.
Today, the Consumer Health divison offers to consumers some of the world’s best-known and most trusted over-the-counter medications，nutritional supplements and other self-care products. The portfolio includes strong brands in selected categories in which the company competes, including Allergy, Analgesics, Cardiovascular Risk Prevention, Cough & Cold, Dermatology, Gastrointestinals, Dietary Supplements.
Crop Science Division
Bayer’s Crop Science division is aligned with the long-term trends of the agricultural markets. The aim is to help shape the future of the agricultural industry with innovative solutions that enable the production of sufficient high-quality food, animal feed and renewable raw materials for a growing world population despite the limited amount of available arable land.
We want to contribute to global food security through an environmentally friendly and sustainable increase in agricultural productivity. Our strength in innovation is intended to benefit both our customers and society as a whole and be the source of our long-term growth.
Bayer has been active for over 60 years in Chinese agriculture, marked with constant efforts to introduce new technologies to Chinese farmers, ranging from the launches of products in recent years covering a large range of crops, namely rice, corn, wheat, vegetables and fruits, to services provided to farmers on crop protection solutions, safe use of agrichemicals and application technologies. As a global player, Bayer’s production site in Hangzhou is not only supplying products for domestic use, but also manufacturing for farmers in the rest of Asia as well as North and Latin America.
The Crop Science Division has also been in cooperation with authorities such as the Ministry of Agriculture, The National Agro-Tech Extension and Service Center, organizations such as the Chinese Academy of Agricultural Sciences, as well as joint efforts with public partners to develop sustainable agriculture in China.
Through the latest technology and decision science, we make the company's operation and agriculture to a higher level and realize the digital transformation. We accelerate our and our partners' research with more advanced solutions, digital tools and data analysis. We use cutting-edge technology to help growers integrate data so as to ensure more efficient use of resources and tap the potential in agricultural. We help growers practice sustainable agricultural and manage the farmland sufficiently by making use of the data at hand. We customize solutions to the needs of growers. We persist in innovation so that we can make crop management more environment friendly, with higher economic benefits and higher quality.
Bayer’s business unit Animal Health offers a number of products for farm and companion animals. Bayer is one of the leading suppliers of veterinary products in China with its head office and a Good Manufacturing Practice certified plant in Chengdu, Sichuan province.